怀孕期间甲福尔的有效性和安全性:最新情况
Stavroula A Paschou1, Almog Shalit2, Eleni Gerontiti2
1Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. s.a.paschou@gmail.com.
Endocrine
|October 5, 2023
概括
在母亲的妊娠糖尿病 (GDM) 中,甲胺显示出与胰岛素相比的血糖控制. 虽然对于新生儿来说通常是安全的,但潜在的风险,如早产和以后的代谢问题需要进一步的研究.
科学领域:
- 产科和妇科 产科和妇科
- 周围生理学 周围生理学
- 内分泌学 在内分泌学.
背景情况:
- 在全球范围内,妊娠糖尿病 (GDM) 的患病率正在上升.
- 胰岛素是黄金标准,但在怀孕期间使用甲素仍有争议.
- 需要在怀孕期间对甲福明的综合疗效和安全性数据.
研究的目的:
- 审查梅特福林对患有GDM的母亲的疗效和安全性.
- 评估甲福明对新生儿结局的影响.
- 评估对后代健康的长期影响.
主要方法:
- 对怀孕中甲福明的现有研究进行系统审查.
- 分析母亲的血糖控制,体重增加和高血压疾病.
- 评估新生儿不良事件和长期代谢编程.
主要成果:
- 在母亲身上,美特福林能够实现与胰岛素相比的血糖控制.
- 它可以减少母亲的体重增加和高血压疾病.
- 没有先天性异常或重大新生儿不良事件的风险增加;观察到新生儿低血糖症的减少.
- 与早产增加和出生体重降低有争议的关联.
- 可能会改变胎儿编程,增加儿童肥胖和代谢综合征的风险.
结论:
- 甲胺是有效和安全的孕产妇GDM管理与潜在的好处.
- 新生儿安全概况在很大程度上令人放心,降低了低血糖.
- 人们仍然担心早产,低出生体重和长期代谢编程.
- 进一步的研究至关重要,以解决关于在怀孕期间使用甲福明的持续问题.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
215
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
215
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Pathophysiology of Diabetes
959
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
959
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
196
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
196
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
188
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
188


